BTEE.L vs. BIOT.L
BTEE.L (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)) and BIOT.L (L&G Pharma Breakthrough UCITS ETF - USD Accumulating ETF) are both Health & Biotech Equities funds - BTEE.L tracks the NASDAQ Biotechnology TR USD while BIOT.L tracks the Solactive Pharma Breakthrough Value Index Net Total Return. Both are passively managed. Over the past 5 years, BTEE.L returned 5.78%/yr vs 2.83%/yr for BIOT.L. Their correlation of 0.82 suggests significant overlap in exposure. BTEE.L charges 0.35%/yr vs 0.49%/yr for BIOT.L.
Performance
BTEE.L vs. BIOT.L - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, BTEE.L achieves a 14.55% return, which is significantly higher than BIOT.L's 8.27% return.
BTEE.L
- 1D
- 0.32%
- 1M
- 8.88%
- 6M
- 12.51%
- YTD
- 14.55%
- 1Y
- 49.20%
- 3Y*
- 17.34%
- 5Y*
- 5.78%
- 10Y*
- —
BIOT.L
- 1D
- 0.31%
- 1M
- 7.79%
- 6M
- 7.56%
- YTD
- 8.27%
- 1Y
- 33.81%
- 3Y*
- 10.20%
- 5Y*
- 2.83%
- 10Y*
- —
BTEE.L vs. BIOT.L - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|---|
BTEE.L iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) | 14.55% | 32.76% | -1.61% | 5.72% | -11.87% | -0.47% | 27.48% | 25.64% | -13.61% |
BIOT.L L&G Pharma Breakthrough UCITS ETF - USD Accumulating ETF | 8.27% | 36.47% | -5.31% | -9.28% | -8.41% | -3.60% | 28.29% | 13.02% | -4.34% |
Correlation
The correlation between BTEE.L and BIOT.L is 0.88, indicating a strong positive relationship between their price movements. Combining them offers limited diversification - they tend to fall together during downturns.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.88 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.82 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.83 |
Correlation (All Time) Calculated using the full available price history since Mar 5, 2018 | 0.82 |
The correlation between BTEE.L and BIOT.L has been stable across timeframes, ranging from 0.82 to 0.88 - a consistent structural relationship.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
BTEE.L vs. BIOT.L — Risk / Return Rank
BTEE.L
BIOT.L
BTEE.L vs. BIOT.L - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) (BTEE.L) and L&G Pharma Breakthrough UCITS ETF - USD Accumulating ETF (BIOT.L). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| BTEE.L | BIOT.L | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.74 | ||
| Sortino ratioReturn per unit of downside risk | +0.95 | ||
| Omega ratioGain probability vs. loss probability | 1.39 | 1.28 | +0.11 |
| Calmar ratioReturn relative to maximum drawdown | 6.41 | 3.52 | +2.89 |
| Martin ratioReturn relative to average drawdown | 19.12 | 10.12 | +8.99 |
Loading charts...
Drawdowns
BTEE.L vs. BIOT.L - Drawdown Comparison
The maximum BTEE.L drawdown since its inception was -38.29%, which is greater than BIOT.L's maximum drawdown of -34.44%. Use the drawdown chart below to compare losses from any high point for BTEE.L and BIOT.L.
Loading charts...
Drawdown Indicators
| BTEE.L | BIOT.L | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -38.29% | -34.44% | -3.85% |
Max Drawdown (1Y)Largest decline over 1 year | -7.64% | -9.55% | +1.91% |
Max Drawdown (3Y)Largest decline over 3 years | -26.76% | -19.91% | -6.85% |
Max Drawdown (5Y)Largest decline over 5 years | -38.29% | -33.80% | -4.49% |
Current DrawdownCurrent decline from peak | -4.35% | -5.72% | +1.37% |
Average DrawdownAverage peak-to-trough decline | -13.35% | -13.31% | -0.04% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 2.57% | 3.33% | -0.76% |
Volatility
BTEE.L vs. BIOT.L - Volatility Comparison
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) (BTEE.L) has a higher volatility of 6.46% compared to L&G Pharma Breakthrough UCITS ETF - USD Accumulating ETF (BIOT.L) at 6.08%. This indicates that BTEE.L's price experiences larger fluctuations and is considered to be riskier than BIOT.L based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| BTEE.L | BIOT.L | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 6.46% | 6.08% | +0.38% |
Volatility (6M)Calculated over the trailing 6-month period | 15.52% | 15.54% | -0.02% |
Volatility (1Y)Calculated over the trailing 1-year period | 20.37% | 20.18% | +0.19% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 21.20% | 18.62% | +2.58% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 22.48% | 19.50% | +2.98% |
BTEE.L vs. BIOT.L - Expense Ratio Comparison
BTEE.L has a 0.35% expense ratio, which is lower than BIOT.L's 0.49% expense ratio.
Dividends
BTEE.L vs. BIOT.L - Dividend Comparison
BTEE.L's dividend yield for the trailing twelve months is around 0.23%, while BIOT.L has not paid dividends to shareholders.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
BIOT.L L&G Pharma Breakthrough UCITS ETF - USD Accumulating ETF | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
BTEE.L iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) | 0.23% | 0.37% | 0.46% | 0.39% | 0.44% | 0.25% | 0.17% | 0.14% | 0.07% |
Frequently Asked Questions
BTEE.L and BIOT.L have a correlation of 0.88, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
On fees, BTEE.L is cheaper at 0.35% per year. The better choice depends on whether you care most about return, fees, risk, or income.
BTEE.L is cheaper with a 0.35% expense ratio, compared with 0.49% for BIOT.L.
BTEE.L tracks NASDAQ Biotechnology TR USD, while BIOT.L tracks Solactive Pharma Breakthrough Value Index Net Total Return. They also come from different issuers: iShares and L&G. Their fees differ too: 0.35% for BTEE.L and 0.49% for BIOT.L.
Find the right allocation for BTEE.L and BIOT.L
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer